CN1920020A - Gene engineering producing method of antibacterial peptide Pexiganan - Google Patents
Gene engineering producing method of antibacterial peptide Pexiganan Download PDFInfo
- Publication number
- CN1920020A CN1920020A CNA2005100148334A CN200510014833A CN1920020A CN 1920020 A CN1920020 A CN 1920020A CN A2005100148334 A CNA2005100148334 A CN A2005100148334A CN 200510014833 A CN200510014833 A CN 200510014833A CN 1920020 A CN1920020 A CN 1920020A
- Authority
- CN
- China
- Prior art keywords
- pexiganan
- gene engineering
- seq
- antibacterial peptide
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010062940 pexiganan Proteins 0.000 title claims abstract description 28
- KGZGFSNZWHMDGZ-KAYYGGFYSA-N pexiganan Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 KGZGFSNZWHMDGZ-KAYYGGFYSA-N 0.000 title claims abstract description 26
- 229950001731 pexiganan Drugs 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 title abstract description 8
- 239000003910 polypeptide antibiotic agent Substances 0.000 title description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 6
- 239000013604 expression vector Substances 0.000 claims description 12
- 230000004927 fusion Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 abstract description 7
- 108020004705 Codon Proteins 0.000 abstract description 5
- 230000007910 cell fusion Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108060003100 Magainin Proteins 0.000 description 2
- 238000005267 amalgamation Methods 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention relates the antibiosis peptide Pexiganan gene engineering expression method, comprising synthesized encoding Pexiganan DNA sequence, which is connected with the carrier to express and purify. The encoding Pexiganan DNA sequence adopts codons which is used high frequency, reducing the mismatch rate. The Tm value is moderate, and the Pexiganan expressed in procaryotic cell fusion expression system is 48-50% of total protein.
Description
Technical field
The invention belongs to gene engineering technology field, relate in particular to the gene engineering expression method of antibacterial peptide.
Background technology
All kinds of diseases that antibiotic discovery makes people cause cause pathogeny imcrobe infection are no longer at a loss what to do, and the protection human health is made a great contribution.But, along with antibiotic widespread use, cause pathogenic strains constantly to produce resistance, some are the very effective controlled communicable disease of microbiotic in the past, and are revivable in recent years.And because chemical sproof continuous enhancing and spreading, it is powerless that existing microbiotic has seemed.Antibiotic in addition generally abuse and drug residue, problems such as some antibiotic anaphylaxis have been on the rise and have become increasingly conspicuous, and the antibiotic preparation that presses for new class is solved.
Face the urgency of bacterial drug resistance challenge greatly and current situation, investigators explore and the present diverse novel antibacterial medicine of mechanism of action with all strength.
Antibacterial peptide extensively is present in the multiple organism, be organism to external world pathogen infect and a series of immunoreactive product that produces, its molecular weight is little, stable performance has stronger broad-spectrum antimicrobial ability.This class antibacterial peptide acts on microbial film (cytolemma, adventitia), destroy its barrier and reach the effect of killing and wounding bacterial cell, has " traditional microbiotic " incomparable superiority simultaneously: can not induce the generation of drug resistance strain, promise to be antiseptic-germicide of new generation.Pexiganan is a micromolecule polypeptide of being made up of 22 amino-acid residues, its primary structure is: Gly-Ile-Gly-Lys-Phe-Leu-Lys-Lys-Ala-Lys-Lys-Phe-Gly-Lys-Ala-Phe-Val-Lys-Ile-Leu-Lys-Lys-NN2, theoretical molecular is: 2.4Kda, derive from the analogue of xenopous laevis epithelium antibacterial peptide magainin family, correlative study shows, such antibacterial peptide has antimicrobial spectrum (the Yigong Ge of broad, Dorothy L.et al, In Vitro AntibacterialProperties of Pexiganan, an Analog of Magainin, Antimicrobial Agents and Chemotherapy, 1999,43:782-788.Bessalle, R., A.Kapitkovshy, et al.All D-magainin:chirality antimicrobial activity, andproteolytic resistance.FEBS Lett.274:151-155), to multiple gram-positive microorganism, Gram-negative bacteria, anerobe and fungi all have anti-microbial activity.Pexiganan has carried out the II clinical trial phase at present abroad, is mainly used in the treatment of diabetic infection.Because content is limited in the normal cell tissue, directly obtain very difficulty of Pexiganan.The Pexiganan of open report is the chemosynthesis product at present, the chemical synthesis complex process, and the cost height, its production process is used a large amount of organic solvents, contaminate environment.
Summary of the invention
Technical problem to be solved
The present invention is intended to solve the problem of utilizing engineered method efficient expression antimicrobial peptides Pexiganan.
Technical scheme
The invention provides a kind of genetically engineered and produce the method for Pexiganan.By analyzing the structure of Pexiganan, the codon of design intestinal bacteria preference, the dna sequence dna of composite coding Pexiganan, see sequence table SEQ ID NO.1 and SEQ IDNO.2, being connected to suitable expression vector expresses and purifying, this expression vector can be any carrier that is suitable for escherichia coli expression, molecular weight features of smaller according to antibacterial peptide, preferred fusion expression vector, as pBS, pTrx, pTrxFus etc., preferred especially GST fusion expression vector, the carrier of pGEX system and pET system (available from amersham pharmaciabiotech company) for example, because gst fusion protein is easy to the amalgamation and expression of small-molecular peptides, molecular weight has certain difference between purpose peptide and the fusion rotein in view of purifying needs, and the easier purifying of so little peptide is thorough.And for better being suitable for the cutting of purpose peptide.
SEQ ID NO.1 and SEQ ID NO.2 can adopt ordinary method synthetic with the nucleic acid automatic DNA synthesizer DNA.
The Pexiganan of gene engineering expression, 5 strain streptococcus aureus Staphylococcus aureus minimal bactericidal concentration (MIC) to different sources are 2～6ug/ml, to 5 Pseudomonas aeruginosa strain Pseudomonas aeruginosa (Pseudomonas aeruginosa) minimal bactericidal concentration (MIC), the 4～8ug/mL of different sources.Other all had good germicidal action as suis, Bacillus proteus, dysentery bacterium, Corynebacterium diphtheriae etc.
Beneficial effect
Genetically engineered provided by the invention is produced the method for Pexiganan, high abundance and the high codon of laws of use in intestinal bacteria have been adopted, repeat few between whole sequence of codon and the codon, reduced the mispairing probability in reproduction process, the Tm value is moderate, the Pexiganan that expresses in prokaryotic cell prokaryocyte amalgamation and expression system accounts for 48～50% of bacterial protein.
Description of drawings
The building process diagram of Pexiganan expression vector.
Embodiment
Below in conjunction with embodiment, it is bright to specify this law.
The used restriction endonuclease of the present invention, ligase enzyme, other molecular biology reagent and bacterial strain E.coli DH5 α are available from Promega company.The preparation of electrophoresis, competent cell, transform method that the equimolecular biological method adopts " molecular cloning experiment guide " and carry out that ((Sambrool J.) waits work to Sa nurse Bruce, and Huang Peitang etc. translate, molecular cloning experiment guide (the 3rd edition), Beijing, Science Press, 2002,8).Plasmid extracts, and adopts Shanghai to give birth to worker's test kit K192, carries out according to operation instruction.
Embodiment 1
The gene engineering expression of Pexiganan
The structure of expression vector and the acquisition of transformant
According to a conventional method respectively with nucleic acid SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4 and SEQID NO.5 synthesize on the plasmid pUC18 carrier, SEQ IDNO.1-pUC18 enzyme is cut with SmaI (ccc/ggg)+EcoRI (g/aattc) according to specification sheets, low melting-point agarose method (" molecular cloning ") reclaims small pieces, with PhsAI (gacNN/NNgtc)+EcoRI (g/aattc) carrier pET42a (+) being carried out enzyme cuts, the low melting-point agarose method reclaims big segment, connect the recovery product according to specification sheets with the T4DNA ligase enzyme, can obtain to contain the expression vector of dna sequence dna of Pexiganan of encoding, expression vector is transformed into the competent cell of freshly prepd bacillus coli DH 5 alpha, screening is also identified transformant, ordinary method is extracted plasmid, and is errorless through the sequencing sequence.
Abduction delivering detects and identifies
The LB flat board that transformant contrast pET42a (+) BL21 (DE3) plys S rules respectively and contains kantlex 30ug/ml, the single colony inoculation of 37 ℃ of cultivations contains the LB meat soup 20ml of kantlex 30ug/ml; And blank BL21 (DE3) plys S colony inoculation does not contain antibiotic LB meat soup 20ml.When the OD value reaches 0.6, add IPTG respectively to final concentration 1mM, 37 ℃ of abduction deliverings 2～3 hours.5, centrifugal 5 minutes of 000g keeps supernatant, usefulness 20mM TrisHCl (pH8.0) washing, and 5, centrifugal 5 minutes of 000g, last cleer and peaceful precipitation is stored in-80 ℃ and is used for electrophoresis detection.At 28～29KDa. molecular weight band is arranged, be fusion rotein (the about 28.4KDa of molecular weight), fusion protein expression is respectively 48%, 50%, 35%, 45% and 40%.
Purifying
GSTrap FF post is connected use with HiTrap Benzamidine FF (high sub) (GE Healthcare-formerly AmershamBiosciences-Products) post, use AKTA Prime (amersham pharmacia biotech company instrument) online treatment, sample cutting and Factor Xa remove a step and finish.Press GSTrap FF post and HiTrap Benzamidine FF (high sub) specification sheets, be used the Prime online treatment, concentrate and obtain pexiganan, according to the SDS-PAGE method (Shi Jihong etc. of little peptide molecule, use the discussion of SDS-PAGE demonstration micromolecule polypeptide technology, the biotechnology progress, 2001, Vol21, No.1,38～41), SDS-PAGE electrophoresis silver dyes its molecular weight of detection and is about 2.4KDa, and sequencing is consistent with bibliographical information.
Antibacterial effect detects
Method: measure (United States Patent (USP) 6,337, on January 8th, 314,2002) by inhibition zone and bacteriocidal concentration.
Obtain the Pexiganan of gene engineering expression according to the method for embodiment 1, to different sources (reference culture streptococcus aureus S.aureus, CMCC (B) 26003 separates staphylococcus aureus strains with the hospital clinical case) 5 strain streptococcus aureus Staphylococcus aureus minimal bactericidal concentration (MIC) be 2～6ug/ml (abroad the experiment and chemosynthesis product MIC bacteriocidal concentration be 16～32ug/ml), (abroad experiment and chemosynthesis product MIC bacteriocidal concentration are 8～32ug/mL) to 5 strain Pseudomonasaeruginosa Pseudomonas aeruginosa (Pseudomonas aeruginosa) minimal bactericidal concentration (MIC), the 4～8ug/mL of different sources (reference culture Pseudomonas aeruginosa Pseudomonas aeruginosaMignla, CMCC (B) 10104 separates pseudomonas aeruginosa strains with the hospital clinical case).
The nucleotides sequence tabulation
SEQ?ID?NO.1
gggatcggca?aattcctgaa?gaaagcgaag?aaattcggca?aggcgttcgt?gaaaatcctg 60
aagaaa 66
SEQ?ID?NO.2
gggatcggca?agttcctgaa?gaaggcgaag?aagttcggca?aggcgttcgt?gaagatcctg 60
aagaag 66
SEQ?ID?NO.3
gggataggta?agtttcttaa?aaaggccaaa?aagtttggaa?aagcatttgt?aaagatactt 60
aaaaag 66
SEQ?ID?NO.4
gggatcggta?agttcctgaa?gaaggctaag?aaattcggta?aggctttcgt?gaagatcctg 60
aagaag 66
SEQ?ID?NO.5
gggatcggta?aattcctgaa?aaaagctaaa?aaattcggta?aggctttcgt?gaaaatcctg 60
aaaaaa 66
Claims (3)
1. the genetic engineering process for preparing of a Pexiganan, the dna sequence dna that comprises composite coding Pexiganan, be connected to suitable expression vector and express and purifying, the dna sequence dna of the Pexiganan that wherein encodes is sequence table SEQ ID NO.1 or SEQ ID NO.2.
2. according to the method for the production Pexiganan of claim 1 or 2, wherein used expression vector is a fusion expression vector.
3. according to the method for the production Pexiganan of claim 4, wherein used expression vector is the GST carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100148334A CN1920020A (en) | 2005-08-24 | 2005-08-24 | Gene engineering producing method of antibacterial peptide Pexiganan |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100148334A CN1920020A (en) | 2005-08-24 | 2005-08-24 | Gene engineering producing method of antibacterial peptide Pexiganan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1920020A true CN1920020A (en) | 2007-02-28 |
Family
ID=37777871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005100148334A Pending CN1920020A (en) | 2005-08-24 | 2005-08-24 | Gene engineering producing method of antibacterial peptide Pexiganan |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1920020A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011069280A1 (en) * | 2009-12-11 | 2011-06-16 | Wu Xiaoyan | Antimicrobial pexiganan analogue and preparation process thereof |
-
2005
- 2005-08-24 CN CNA2005100148334A patent/CN1920020A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011069280A1 (en) * | 2009-12-11 | 2011-06-16 | Wu Xiaoyan | Antimicrobial pexiganan analogue and preparation process thereof |
| CN102656184A (en) * | 2009-12-11 | 2012-09-05 | 吴晓琰 | Antimicrobial pexiganan analogue and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tencza et al. | Lentivirus-derived antimicrobial peptides: increased potency by sequence engineering and dimerization | |
| CN111019001B (en) | Recombinant lysozyme antibacterial peptide fusion protein and preparation method and application thereof | |
| CN101173004A (en) | Insect antimicrobial peptide Thanatin and method for producing deletion mutant thereof | |
| CN101173005A (en) | Insect antimicrobial peptide Thanatin derivant, producing method and uses of the same | |
| CN101817883A (en) | Housefly cecropin-human lysozyme fusion protein, and preparation method and application thereof | |
| WO2009131548A1 (en) | Multimeric forms of antimicrobial peptides | |
| CN112301021B (en) | Enlysin and perforin composition for resisting escherichia coli phage expression and preparation method and application thereof | |
| Li et al. | Production of bioactive human beta-defensin-4 in Escherichia coli using SUMO fusion partner | |
| CN107857803A (en) | Natural antibacterial peptide and its application | |
| Tian et al. | Multimerization and fusion expression of bovine lactoferricin derivative LfcinB15-W4, 10 in Escherichia coli | |
| CN112094833B (en) | Bacteriostatic protein, and coding gene, application and strain thereof | |
| CN1920020A (en) | Gene engineering producing method of antibacterial peptide Pexiganan | |
| CN1966709B (en) | Process for preparing recombinant Sinkiang domestic silkworm antibiotic peptide, Sinkiang domestic silkworm antibiotic peptide therefrom, and use thereof | |
| Yin et al. | A specific antimicrobial protein CAP-1 from Pseudomonas sp. isolated from the jellyfish Cyanea capillata | |
| CN105622763A (en) | Antimicrobial peptide fusion protein and preparation method and application thereof | |
| CN104987367A (en) | Preparation method of artificial antibacterial peptide PR39-R1T and application thereof | |
| CN101886081A (en) | Procambarus clarkia chitin peptide gene and encoded chitin peptide and application thereof | |
| CN1920019A (en) | Gene engineering producing method of antibacterial peptide IB-367 | |
| CN103483433B (en) | Novel effective cerecidin and application thereof | |
| CN103467580B (en) | Preparation method and application of artificial antimicrobial peptide MA-D4 | |
| Jeyarajan et al. | Bioproduction and characterization of epinecidin-1 and its variants against multi drug resistant bacteria through in silico and in vitro studies | |
| CN114276413A (en) | Preparation method of artificial antibacterial peptide G3 | |
| CN111481660B (en) | Pharmaceutical composition containing depolymerizing enzyme with function of degrading extracellular polymers of klebsiella pneumoniae | |
| CN116874614B (en) | Antibacterial polypeptide APH171 with high activity and low cracking effect, and preparation method and application thereof | |
| CN110386972B (en) | Antibacterial polypeptide Pb2-1 or PCL-1 and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |